ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

Teresa Lambe, Alexandra J. Spencer, Kelly Thomas, Karen Gooch, Stephen Thomas, Andrew White, Holly Humphries, Daniel Wright, Sandra Belij-Rammerstorfer, Nazia Thakur, Carina Conceicao, Robert Watson, Leonie Alden, Lauren Allen, Marilyn Aram, Kevin Bewley, Emily Brunt, Phillip Brown, Breeze Cavell, Rebecca CobbSusan Fotheringham, Ciaran Gilbride, Deborah Harris, Catherine M.K. Ho, Laura Hunter, Chelsea L. Kennard, Stephanie Leung, Vanessa Lucas, Didier Ngabo, Kathryn Ryan, Hannah Sharpe, Charlotte Sarfas, Laura Sibley, Gillian Slack, Marta Ulaszewska, Nadina Wand, Nathan Wiblin, Fergus V. Gleeson, Dalan Bailey, Sally Sharpe, Susan Charlton, Francisco Javier Salguero Bodes, Miles Carroll, Sarah C. Gilbert*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)
19 Downloads (Pure)


Vaccines against SARS-CoV-2 are urgently required, but early development of vaccines against SARS-CoV-1 resulted in enhanced disease after vaccination. Careful assessment of this phenomena is warranted for vaccine development against SARS CoV-2. Here we report detailed immune profiling after ChAdOx1 nCoV-19 (AZD1222) and subsequent high dose challenge in two animal models of SARS-CoV-2 mediated disease. We demonstrate in rhesus macaques the lung pathology caused by SARS-CoV-2 mediated pneumonia is reduced by prior vaccination with ChAdOx1 nCoV-19 which induced neutralising antibody responses after a single intramuscular administration. In a second animal model, ferrets, ChAdOx1 nCoV-19 reduced both virus shedding and lung pathology. Antibody titre were boosted by a second dose. Data from these challenge models on the absence of enhanced disease and the detailed immune profiling, support the continued clinical evaluation of ChAdOx1 nCoV-19.

Original languageEnglish
Article number915
JournalCommunications Biology
Publication statusPublished - 26 Jul 2021

Bibliographical note

Funding Information: SCG is co-founder and board member of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on a patent covering the use of ChAdOx1-vectored vaccines and a patent application covering this SARS-CoV-2 vaccine. TL is named as an inventor on a patent application covering this SARS-CoV-2 vaccine and consultant to Vaccitech. All other authors had no competing interests.

Open Access:This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Publisher Copyright: © The Author(s) 2021

Citation: Lambe, T., Spencer, A.J., Thomas, K.M. et al. ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. Commun Biol 4, 915 (2021).



Dive into the research topics of 'ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models'. Together they form a unique fingerprint.

Cite this